Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on March 2, 2020, announcing its fourth quarter and full-year 2019 financial results. While the full financial details are not elaborated in the provided text, the filing serves as a notification of the earnings release and incorporates by reference the associated press release for comprehensive information. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance, operational achievements, and management's outlook.
Key Highlights
- 1Announcement of Q4 and Full-Year 2019 financial results on March 2, 2020.
- 2Inclusion of a press release (Exhibit 99.1) containing detailed financial and operational information.
- 3Disclosure of the suggested list price for tislelizumab in China: RMB 10,688 per 100mg.
- 4Tislelizumab received NMPA approval in China for classical Hodgkin's lymphoma (cHL) in patients with at least two prior therapies.
- 5Tislelizumab is currently only approved for use within China.
- 6The company provided an update on Q4 2019 business highlights and expected milestones for 2020.
- 7Information from the press release regarding business highlights and forward-looking statements is incorporated by reference.